Combination / selection rationale: Low aqueous solubility makes carrier selection important; phospholipid encapsulation differs from a simple powder blend.
Published evidence / source details: A 2013 study prepared DOPC/DODA-PEG2000 fisetin liposomes, approximately 173.5 nm with 58% encapsulation, followed by cell and mouse experiments. It provides carrier characterization, not an oral raw-powder trial.
Development insights: Compare powder suspension, physical mixture and encapsulated material. Measure total/free fisetin, size, encapsulation and leakage; select suitable carriers and validate the actual process before calling a material liposomal.
Evidence scope: A specific experimental delivery system, without absorption, clinical or nanoscale-supply claims for this powder.
2013 · Seguin et al. · DOI 10.1016/j.ijpharm.2013.01.050 ↗